Main Article Content
Abstract
Using polyethylene glycol (PEG) to enhance drug solubility, bioavailability, and immune response qualities, the study aims to analyze the advantages and difficulties of target-site drug delivery methods. This approach reduces reticuloendothelial system clearance, improves pharmacokinetics, lowers immunogenicity, and aids in the passage of medications across the blood-brain barrier. PEG and its derivatives are increasingly being employed to change medicinal molecules, providing a way around some of the problems with traditional drug formulations.
The review looks at several PEGylation strategies, including innovative techniques for reversing multi-drug resistance in nanocarriers. The immunogenic response to PEG, commonly known as "anti-PEG antibodies," and stability issues that necessitate the development of countermeasures are among the disadvantages of PEGylation despite its many advantages. Listing FDA-approved PEGylated drugs and highlighting their therapeutic benefits and clinical applications across a variety of medical disciplines takes up a significant portion of the study.
The study also looks extensively at PEG's safety and efficacy in drug formulations, as well as the regulatory framework surrounding it. The review covers lipid-based nanocarriers such as liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), Gold Nanoparticles and DEP® Technology (PEGylated Dendrimer Drug Delivery Platform) in addition to PEGylation. These nanocarriers are becoming increasingly important in drug delivery systems because they can encapsulate medications, enhance bioavailability, and target certain tissues or cells. This process ensures that the final product meets the necessary standards for quality, safety, and efficacy.